Illegal cannabis use is common among Danes with multiple sclerosis

Autor: PS Sorensen, S. R. Andresen, Helle Bach Søndergaard, Annette Bang Oturai, Melinda Magyari, Finn Sellebjerg, Stefan Gustavsen

Publikováno v: Gustavsen, S, Sondergaard, H B, Andresen, S R, Magyari, M, Sorensen, P S, Sellebjerg, F & Oturai, A B 2019, ' Illegal cannabis use is common among Danes with multiple sclerosis ', Multiple Sclerosis and Related Disorders, vol. 33, pp. 5-12 . https://doi.org/10.1016/j.msard.2019.05.008

Background: Use of cannabis to alleviate multiple sclerosis (MS)-related symptoms is increasing. Due to strict regulations, only a minority of MS patients receive cannabis-based prescription drugs. The extent of recreational and medical cannabis use

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82bf72cb4890ae90a1d5fcdcc2a6b309
https://pure.au.dk/portal/da/publications/illegal-cannabis-use-is-common-among-danes-with-multiple-sclerosis(0810d884-ae99-4b72-a0e1-47a2e52a5969).html

The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis

Autor: PS Sorensen, M Møller, Helle Bach Søndergaard, Finn Sellebjerg, Annette Bang Oturai, Nils Koch-Henriksen

Publikováno v: Møller, M, Søndergaard, H B, Koch-Henriksen, N, Sorensen, P S, Sellebjerg, F & Oturai, A B 2014, ' The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis ', Acta Neurologica Scandinavica, vol. 129, no. 1, pp. 27-31 . https://doi.org/10.1111/ane.12145

OBJECTIVE: The chemokine receptor CCR5 may be important for the recruitment of pathogenic T cells to the CNS in multiple sclerosis (MS). We hypothesized that this chemokine receptor might still be important for T-cell migration during treatment with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::715f23b8fb2dbc76f44a2fa4f2a047f9
https://pubmed.ncbi.nlm.nih.gov/23668375

Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-beta

Autor: Egon Stenager, Dan Hesse, Jette L. Frederiksen, Klaus Bendtzen, Mads Ravnborg, A. Heltberg, Karen Schreiber, Finn Sellebjerg, N. Koch-Henriksen, PS Sorensen

Publikováno v: Hesse, D, Frederiksen, J L, Koch-Henriksen, N, Schreiber, K, Stenager, E, Heltberg, A, Ravnborg, M, Bendtzen, K, Sellebjerg, F & Sorensen, P S 2009, ' Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-beta ', European Journal of Neurology, vol. 16, no. 1, pp. 43-7 . https://doi.org/10.1111/j.1468-1331.2008.02336.x
Hesse, D, Frederiksen, J L, Koch-Henriksen, N, Schreiber, K, Stenager, E, Heltberg, A, Ravnborg, M, Bendtzen, K, Sellebjerg, F & Sørensen, P S 2009, ' Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-beta ', European Journal of Neurology, vol. 16, no. 1, pp. 43-7 . https://doi.org/10.1111/j.1468-1331.2008.02336.x

Udgivelsesdato: 2009-Jan BACKGROUND AND PURPOSE: Neutralizing antibodies (NAbs) appearing during treatment with Interferon-beta (IFN-beta) reduce or abolish bioactivity and therapeutic efficacy. Initial combination therapy with methylprednisolone (MP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::515316a510990224a5431e0454e3382e
https://portal.findresearcher.sdu.dk/da/publications/75eb4eb0-858a-11de-9c46-000ea68e967b

Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?

Autor: PS Sorensen, Nils Koch-Henriksen, Klaus Bendtzen

Publikováno v: Multiple sclerosis (Houndmills, Basingstoke, England). 13(5)

Neutralising antibodies (NAbs) against interferon (IFN)-β reduce the treatment effect in multiple sclerosis (MS). However, data from pivotal trials of IFN-β in MS suggest that NAb-positive patients may have a reduced relapse rate during the first s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6358872f62ec646ecb97e9633657a425
https://pubmed.ncbi.nlm.nih.gov/17548440

Leaderless foot-and-mouth disease virus serotype O did not cause clinical disease and failed to establish a persistent infection in cattle.

Autor: Litz, Benedikt, Sehl-Ewert, Julia, Breithaupt, Angele, Landmesser, Anja, Pfaff, Florian, Romey, Aurore, Blaise-Boisseau, Sandra, Beer, Martin, Eschbaumer, Michael

Publikováno v: Emerging Microbes & Infections; Dec2024, Vol. 13 Issue 1, p1-13, 13p